TrialAnnals of oncology : official journal of the European Society for Medical Oncology2009

Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205.

T Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.